Lower WASP expression in PBMC from CML patients in advanced phases correlates with poor OS and re-expression of WASP negatively modulates BCR–ABL1-induced tumorigenesis in vitro and in vivo. The gene discussed is WAS; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.